For the majority of patients diagnosed with pancreatic neuroendocrine tumors (NETs), there is significant malignant potential with a poor prognosis; however, the molecular abnormalities and pathogenesis of pancreatic NETs have not been firmly established. Here, we report that loss of expression of the RNA-binding protein HuD correlates with low p27 Kip1 (p27) levels and poor prognosis in pancreatic NETs. HuD expression was frequently lost in many human pancreatic NETs, and these pancreatic NETs showed aggressive clinicopathological phenotypes with low p27 levels, increased tumor size, higher World Health Organization grade and pT stage of the tumor, and the presence of angioinvasion. Furthermore, loss of HuD was an independent, progression-free prognostic factor in multivariate survival analysis. However, the level of HuR, a member of the same Hu protein family as HuD, was not significantly correlated with pancreatic NET size and progression. Mechanistically, HuD enhanced p27 mRNA translation by interacting with both the 5 ′ -untranslated region (UTR) and the 3 ′ -UTR of p27 mRNA, and consequently suppressed cell cycle progression and tumor growth. In addition, HuD competed with miR-30a-3p for binding to the 3 ′ -UTR of p27 mRNA, suggesting an interplay between HuD and miR-30a-3p in controlling p27 translation. Our results identify HuD as a pivotal suppressor of pancreatic NET growth, and suggest that HuD has potential value as a prognostic factor of pancreatic NETs.
Introduction
Pancreatic neuroendocrine tumors (NETs), which are commonly referred to as 'islet cell tumors', are neuroendocrine tumors derived from the pancreatic endocrine cells present within the islets of Langerhans, and are classified into functional (such as insulinoma, the most prevalent functional pancreatic NET) and non-functional tumors, depending on whether or not they cause hormonal hypersecretion [1] [2] [3] . Most pancreatic NETs are indolent tumors but have significant malignant potential; they constitute the second most common malignancy of the pancreas, and patients with malignant pancreatic NETs have a short survival period [2] [3] [4] [5] [6] . In the past few decades, the incidence and prevalence of pancreatic NETs have increased substantially, although overall survival has remained relatively unchanged [2] [3] [4] [5] . Further advances232 C Kim et al development of personalized and combination therapy to provide prolonged control of, or even a cure for, the disease.
Cell cycle progression in mammals is driven by various complexes of cyclins and cyclin-dependent kinases (CDKs); the CDK inhibitory protein p27 Kip1 (p27, encoded by the gene CDKN1B) suppresses CDK activity and inhibits cell proliferation [7, 8] . Similarly to what has been found in other tumors, several studies have shown that loss of the tumor-suppressive function of p27 is one of the defects in pancreatic NETs, and is associated with their high proliferation, and poor prognosis and shorter overall survival of patients [5, 6, [9] [10] [11] [12] [13] . This defective function of p27 results from its reduced expression and/or cytoplasmic mislocalization [13] [14] [15] [16] [17] [18] . The overall abundance of p27 is regulated at the transcriptional, translational and post-translational levels [7, [13] [14] [15] [16] [17] [18] [19] [20] . However, many studies have demonstrated that, during the cell cycle, oscillations in the abundance of p27 occurred without any changes in p27 mRNA levels [7, [19] [20] [21] . The p27 mRNA contains an internal ribosomal entry site (IRES) in the 5 ′ -untranslated region (UTR) that is necessary for efficient p27 translation [20, 22] . Several RNA-binding proteins (RBPs) have been identified as specific binding factors of the IRES in the p27 mRNA 5 ′ -UTR, and this binding regulates the IRES-dependent translation of p27 mRNA [20, 22] . Furthermore, in contrast to most tumor suppressors, gene mutation or silencing at the CDKN1B locus is rare [12, 19] . These observations indicate that the abundance of p27 is largely regulated by post-transcriptional mechanisms that include translational control [7, [19] [20] [21] [22] . However, whether post-transcriptional regulation of p27 mRNA contributes to the loss of p27 activity in pancreatic NETs, and which factor(s) are directly involved in this regulation, remain unknown.
Here, we identified HuD/ELAVL4 as a key RBP that binds to p27 mRNA and enhances its translation in pancreatic NETs. Furthermore, we provide evidence that loss of HuD is associated with increased tumor size and shorter survival in patients with pancreatic NETs. Four Hu/ELAVL family members have been identified: the largely neuronal members HuB, HuC, and HuD, and the ubiquitous HuR [23] . Our previous study revealed that HuD was also expressed in pancreatic β cells [24] . Hu/ELAVL proteins bind to AU-rich and U-rich RNA elements in the 3 ′ -UTR of target mRNAs and enhance their stability, thus indirectly increasing protein production [23, 25, 26] . Hu/ELAVL proteins can also modulate the translation of target mRNAs; unlike their effects on mRNA stability, they often serve as enhancers or repressors of translation [20, 22, 27] . Kullmann et al showed that HuD and HuR binding to the p27 5 ′ -UTR represses p27 mRNA translation and promotes cell cycle progression in non-neural/neuroendocrine cells [20] . Here, we report that, unlike in the non-neural/neuroendocrine cells, HuD binds to both the 5 ′ -UTR and the 3 ′ -UTR of p27 mRNA, and enhances p27 translation in pancreatic NET cells, leading to cell cycle arrest in the G 1 phase. Accordingly, patients with HuD-negative pancreatic NETs had decreased p27 levels, increased tumor sizes, poor prognosis, and shorter progression-free survival (PFS).
Materials and methods

Patients
This study was approved by the International Review Board of Seoul National University Hospital (SNUH) (H-1602-034-739). We selected 88 patients who had been surgically treated for pancreatic NET, from 1994 to 2012, and obtained their medical records and formalin-fixed paraffin blocks of the tumor tissues from the archives of the department of pathology in SNUH. The criterion of pT stage was based on the exocrine and endocrine pancreas tumor staging of the American Joint Committee on Cancer, 7th edition [28] . The criterion of World Health Organization (WHO) grade was based on the 2017 new classification of neuroendocrine neoplasms [29] . Details are given in supplementary material, Supplementary materials and methods.
Immunohistochemistry (IHC)
Paraffin sections were stained with primary antibodies against HuD, Ki67, and p27, after an antigen retrieval process. Details of the primary antibodies are given in supplementary material, Table S1 . The slides were stained by use of the Ultravision LP kit (Lab Vision, Fremont, CA, USA) or the Envision kit (Dako, Glostrup, Denmark) and a Bond polymer Refine Detection kit (Leica Biosystems, Wetzlar, Germany), and processed with a Bond-Max IHC and in situ hybridization (ISH) slide stainer (Leica Biosystems). Details of interpretation of IHC results are given in supplementary material, Supplementary materials and methods. An H-score was calculated on the basis of the intensity and percentage of positively stained cells, automatically counted by the use of image analysis, and the following categories were assigned [30] . The intensity score (0-3+) was based on digitally measured intensity (range 0-240, black to white), and the range for each group was as follows: 0, 211-240; 1+, 189-210; 2+, 163-188; 3+, 0-162.
HuD suppresses pancreatic NETs through enhancing p27 Kip1 translation 233 β-specific insulin receptor-deficient (βIRKO) mice [24, [31] [32] [33] [34] [35] . βIRWT, βIRKO and Min6 cells were cultured in high-glucose DMEM (Invitrogen) supplemented with 10% FBS (HyClone). Details are given in supplementary material, Supplementary materials and methods.
Biotin pull-down analysis
For in vitro synthesis of biotinylated transcripts, polymerase chain reaction (PCR) fragments were prepared with 5 ′ primers that contained the T7 RNA polymerase promoter sequence (T7, CCAAGCTTCTAATACGACT-CACTATAGGGAGA). Primer pairs used to synthesize DNA templates for the production of biotinylated transcripts spanning p27 mRNA (NM_009875.4) are listed in supplementary material, Table S2 . After purification of the PCR products, biotinylated transcripts were synthesized with the MaxiScript T7 kit (Thermo Fisher Scientific, Waltham, MA, USA) and biotin-CTP (Enzo Life Sciences, Farmingdale, NY, USA). Biotin pull-down assays were performed by incubating whole-cell lysates (200 μg per sample) with 1 μg of purified biotinylated transcripts for 30 min at 25 ∘ C, and then isolating the complexes with streptavidin-coupled Dynabeads (Invitrogen); the bound proteins present in the pull-down material were analyzed by western blotting [24, 36] .
Statistical analyses
Quantitative data are presented as the mean ±standard error of the mean (SEM). 
Results
Loss of HuD expression in human pancreatic NET tissues is correlated with an aggressive clinicopathological phenotype
To investigate the expression patterns of HuD and p27 in human pancreatic NETs, we performed IHC for HuD and p27 in normal pancreas and tumors from patients (n = 88) diagnosed with NETs in the pancreas. Consistent with our previous report [24] , normal tissues showed positive staining of HuD in endocrine islet cells and lack of staining in exocrine tissue ( Figure 1A ; supplementary material, Figure S1 ). Similarly, p27 was expressed mainly in normal islet cells, with little, if any, expression being seen in exocrine tissue ( Figure 1A ). In contrast, we found considerable differences in immunoreactivity across the samples in the tumor cohort, ranging from negative to positive ( Figure 1B ; Table 1 ). The positivity rate for HuD in the 88 human pancreatic NETs was 73.9% (65 of 88 cases), and 26.1% (23 of 88 cases) were negative for HuD ( Figure 1B ; Table 1 ). Considering the positivity of HuD in normal islet cells, its absence in 23 pancreatic NETs is most likely due to aberrant loss of expression. As shown in Table 1 , mitotic counts and proportions of G2 and G3 grade according to the 2017 WHO classification were higher in HuD-negative pancreatic NETs than in HuD-positive pancreatic NETs. G2 and G3 pancreatic NETs are defined as well-differentiated NETs with different proliferative activity, according to the 2017 WHO classification [29] , and we excluded poorly differentiated neuroendocrine carcinoma (small-cell carcinoma and neuroendocrine carcinoma). HuD-negative cases in this study showed the histological features of NET, i.e. a trabecular, solid or ribbon arrangement of round, plump epithelial cells with a salt and pepper chromatin pattern, and these histological features were not different in HuD-positive cases. Other histological features, such as necrosis, a plasmocytoid cell or tubular pattern, desmoplastic stroma, and nuclear pleomorphism, were also compared with HuD expression (supplementary material, Table S3 ). Plasmocytoid cells or a tubular pattern were more frequently found in HuD-negative pancreatic NETs than in HuD-positive pancreatic NETs, but necrosis, desmoplastic stroma and nuclear pleomorphism were not significantly different between HuD-positive and HuD-negative pancreatic NETs. In addition, we observed a positive relationship between HuD and p27 levels in human pancreatic NETs by IHC ( Figure 1C ). The expression of p27 was significantly decreased in HuD-negative pancreatic NETs as compared with HuD-positive pancreatic NETs (H-score for p27 in HuD-negative NETs versus HuD-positive pancreatic NETs: 149.3 ±67.7 versus 209.0 ±58.3; p < 0.001) ( Figure 1D ; supplementary material, Table S4 ).
Next, we determined whether loss of HuD expression was related to pancreatic NET progression by analyzing the association between HuD expression and clinicopathological status in pancreatic NETs. HuD-negative pancreatic NETs had a higher Ki67 index than HuD-positive pancreatic NETs ( Figure 1E ). Statistical analysis showed strong correlations between HuD expression and tumor size (p = 0.006), grade based on the 2017 WHO classification (p < 0.001), mitotic counts (p = 0.001), invasion of other organs (p = 0.003), angioinvasion (p = 0.033), and pT stage (p = 0.004) ( Figure 1F ; Table 1 ). However, there was no significant difference in pN and pM stages between the two groups ( Table 1 ). The frequency of HuD-negative pancreatic NETs was higher in patients who had NET-associated syndromes such as Von Hippel-Lindau (VHL) syndrome and multiple endocrine neoplasia (MEN) than in sporadic patients (Table 1) . Notably, all pancreatic NET patients with MEN were negative for HuD expression. These associations were further confirmed by survival analysis, which suggested a positive correlation between tumoral HuD loss and significantly reduced PFS (mean survival of HuD-negative versus HuD-positive patients, 70 ±11 months versus 181 ±11 months; p < 0.001) ( Figure 1G ; ; p = 0.045) were independent prognostic factors for PFS in patients with pancreatic NET ( Table 2) . As the ubiquitous RBP HuR is closely related to and shares several target mRNAs with HuD [23] , we also evaluated whether HuR expression is correlated with tumor size, growth and progression in the same pancreatic NET cohort. HuR was expressed in most areas of normal pancreas, including islet, acinar and ductal cells (supplementary material, Figure S2 ). Although differences in immunoreactivity for HuR across the samples were observed in the 88 human pancreatic NETs, only six samples (6.8%) were negative for HuR, and its expression was not significantly correlated with pancreatic NET size, growth, and progression (supplementary material, Table S5 ).
HuD inhibits pancreatic NET cell proliferation, cell cycle progression, and tumor growth Insulinoma, an islet cell tumor derived from pancreatic β cells, is one of the most common types of pancreatic NET, in which HuD is expressed [24] and p27 functions as the primary inhibitor of cell cycle progression and proliferation [16, 37] . To investigate the biological significance of HuD expression in the development and progression of pancreatic NET, we performed gain-of-function and loss-of-function studies with Myc-HuD plasmid and HuD small interfering RNA (siRNA), respectively. We used a βTC6 cell line that stably overexpressed HuD (Myc-HuD) and a Min6 cell line with stably silenced HuD expression [HuD short hairpin RNA (shHuD)]. The expression of p27 in βTC6 cells was decreased significantly by silencing of HuD ( Figure 2A ) and was increased by stable overexpression of Myc-HuD (supplementary material, Figure S3A ). However, endogenous p27 mRNA levels in βTC6 cells remained clearly unchanged after knockdown of HuD ( Figure 2B ) or stable overexpression of HuD (supplementary material, Figure S3B ). By performing cell proliferation and colony-forming assays, we found that silencing of HuD increased the proliferative capacity of βTC6 cells as compared with that of cells containing control siRNA (Figure 2C,D) . In contrast, HuD overexpression dramatically reduced the proliferative capacity of βTC6 cells (supplementary material, Figure S3C ,D). To gain insights into the mechanism by which HuD reduces pancreatic NET cell proliferation, we next analyzed differences in cell cycle distributions by flow cytometry after HuD silencing or overexpression. Consistent with the changes in p27 levels after modulating HuD abundance, silencing of HuD directed progression beyond the G 1 /S transition in βTC6 cells (Figure 2E ), whereas G 1 /S arrest was observed in HuD-overexpressing βTC6 cells (supplementary material, Figure S3E ). Similar effects were observed in another insulinoma-derived cell line, Min6, stably expressing control short hairpin RNA (shCtrl) or shHuD; p27 abundance was decreased and cell cycle progression was facilitated in shHuD cells as compared with shCtrl cells (supplementary material, Figure  S4A ,B). Additionally, silencing of HuD increased the proportion of Ki67-positive Min6 cells as compared with control cells (supplementary material, Figure  S4C ). Collectively, these results show that HuD reduces cell proliferation by promoting p27 expression.
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As HuD represses insulin mRNA translation and decreases insulin production [24] , and because insulin is a key growth factor that enhances pancreatic β-cell proliferation by decreasing p27 levels [16, [31] [32] [33] [34] [35] , we examined the potential role of insulin as a mediator of HuD-controlled p27 expression and pancreatic NET cell growth, by using β cells derived from βIRWT or βIRKO mice [24, [31] [32] [33] [34] [35] . There were no significant differences in HuD-controlled p27 expression and cell cycle progression between βIRWT and βIRKO cells (supplementary material, Figure S5A -C). These data suggest that HuD directly regulates p27 expression and cell cycle progression independently of insulin signaling.
The effect of HuD on pancreatic NET cell growth was further confirmed in an in vivo tumor growth assay. As the transplantation of insulinoma cells into normal mice causes death due to hypoglycemia, we transplanted βTC6 cells into BALB/c mice after a single intraperitoneal injection of streptozotocin (200 mg/kg), which is a β-cell toxin that produces a progressive increase in blood glucose levels over time as β cells die, and then directly injected either control or HuD siRNA 238 C Kim et al more rapidly than control siRNA-injected tumors with decreased levels of HuD and p27 ( Figure 2F ; supplementary material, Figure S6C,D) . Consistent with the tumor growth data, blood glucose levels were significantly lower in the HuD siRNA-injected group than in the control siRNA-injected group (supplementary material, Figure S6E ). Taken together, these data indicate that HuD inhibits pancreatic NET cell proliferation in vivo.
HuD binds to both the 5
′ -UTR and the 3 ′ -UTR of p27 mRNA, and enhances its translation in pancreatic NET cells
To investigate the molecular mechanism by which HuD regulates p27 expression, we studied the interaction of HuD with the p27 mRNAs by using ribonucleoprotein (RNP) immunoprecipitation analysis (RNP-IP) in βTC6 cells. The results showed enrichment of p27 mRNA in the HuD immunoprecipitate (IP) as compared with the IgG IP ( Figure 3A ). To map a potential HuD-binding region in p27 mRNA, biotinylated segments spanning the 5 ′ -UTR (5 U), coding region (CR) and 3 ′ -UTR (3 U-1 and 3 U-2) were synthesized, and the RNP complexes of HuD and biotinylated RNAs were detected by biotin pull-down analysis with streptavidin-coated beads followed by western blotting ( Figure 3B ). HuD interacted with both the 5 ′ -UTR and the 3 ′ -UTR of p27 mRNA, but not with the CR or a negative control transcript [spanning the 3 ′ -UTR of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA].
To determine whether the 5 ′ -UTR and 3 ′ -UTR are functional for the regulation of p27 mRNA by HuD, we generated reporter constructs derived from the vector pEGFP-N1 or pEGFP-C1, in which the entire 5 ′ -UTR (pEGFP-p27-5 U) or 3 ′ -UTR (pEGFP-p27-3 U) was inserted before the translation start site or after the translation stop site of the enhanced green fluorescent protein (EGFP) coding region, respectively ( Figure 3C ). Each reporter construct was transfected into siRNA-transfected [control siRNA (siCtrl) or HuD siRNA (siHuD)] or plasmid-transfected (pcDNA or pHuD) βTC6 cells, and EGFP expression was assessed by western blot analysis. Consistent with the results shown in Figure 2A , silencing of HuD selectively decreased EGFP expression in the pEGFP-p27-5 U and pEGFP−p27-3 U groups, but not in the control reporter group (pEGFP) ( Figure 3D ). Conversely, HuD overexpression increased EGFP expression in the pEGFP-p27-5 U and pEGFP-p27-3 U groups, but not in the pEGFP group ( Figure 3D ). These data indicate that HuD can associate with p27 mRNA 5 ′ -UTR and 3
′ -UTR, and that this association promotes p27 production.
To investigate whether HuD enhances translation of p27 mRNA, we carried out polysome analysis in Myc-HuD-overexpressing βTC6 cells. Cytoplasmic extracts from control and HuD-overexpressing cells were fractionated through sucrose gradients, with the lightest components sedimenting at the top (fractions 1 and 2), the small (40S) and large (60S) ribosomal subunits and monosomes (80S) appearing in fractions 3-5, and progressively larger polysomes appearing in fractions 6-12 ( Figure 3E ). Polysome-associated p27 mRNA peaked in fraction 8 in vector-transfected cells, whereas HuD overexpression HuD increased the peak size of p27 mRNA polysomes, which was highest in fraction 9 ( Figure 3E ). The distribution of the housekeeping GAPDH mRNA associated with polysomes largely overlapped between the two groups ( Figure 3E ). Additional evidence that HuD modulates p27 translation was obtained by nascent translation analysis. The incorporation of [
35 S]Met and [ 35 S]Cys into newly synthesized p27 during a short time period (20 min) was decreased by HuD silencing and, conversely, increased by HuD overexpression in the absence of changes in the reference protein GAPDH ( Figure 3F ). Collectively, these results strongly indicate that HuD increases p27 expression by enhancing the translation of p27 mRNA.
miR-30a-3p represses p27 expression and competes with HuD for binding to the p27 3 ′ -UTR
Using three different in silico analyses, we found that miR-30a-3p can potentially target the HuD-binding site in the p27 mRNA 3 ′ -UTR (p27-HuD BS) (positions 2092-2212) and regulate p27 expression. Indeed, ectopic expression of miR-30a-3p in βTC6 cells decreased p27 expression, whereas inhibition of miR-30a-3p increased it ( Figure 4A ). Polysome analysis in βTC6 cells transiently transfected with miR-30a-3p showed that ectopic expression of miR-30a-3p reduced the association of p27 mRNA with polysomes, suggesting a role of miRNA-30a-3p as repressor of p27 translation ( Figure 4B ). This was also supported by nascent translation analysis in βTC6 cells. Either ectopic expression of miR-30a-3p or silencing of HuD decreased p27 translation, whereas ectopic expression of miR-30a-3p after transfection with siHuD further suppressed p27 translation ( Figure 4C ). As miR-30a-3p targets the p27-HuD BS, we sought to determine whether there is any interplay between HuD and miR-30a-3p in controlling p27 expression. RNP-IP analysis with an anti-HuD antibody and normal IgG in βTC6 cells transfected with pre-miR-30a-3p or anti-miR-30a-3p showed that enrichment of p27 mRNA in the HuD IP as compared with the IgG IP was significantly reduced by pre-miR-30a-3p, but conversely, enhanced by anti-miR-30a-3p ( Figure 4D) . Accordingly, ectopic expression of miR-30a-3p in βTC6 cells transfected with siHuD elicited stronger suppression of p27 expression than that in βTC6 cells transfected with siCtrl ( Figure 4E ). To further confirm the functional interplay between HuD and miR-30a-3p in controlling p27 expression, we generated EGFP reporter constructs containing the p27-HuD BS or a mutant p27-HuD BS (p27-HuD BS mut), which lack the seed region for base pairing with miR-30a-3p, after the translation stop site of the EGFP-coding region ( Figure 4F ). Silencing of HuD decreased pEGFP-p27-HuD BS reporter expression, but did not affect the pEGFP-C1 control or pEGFP-p27-HuD BS mut reporter groups ( Figure 4G ). pEGFP-p27-HuD BS reporter expression was also regulated by miR-30a-3p; ectopic expression of miR-30a-3p decreased reporter expression, whereas inhibition of miR-30a-3p increased it (supplementary material, Figure S7 ). However, pEGFP-p27-HuD BS mut reporter expression was not affected by miR-30a-3p ( Figure 4H ). These results suggest that both HuD and miR-30a-3p bind to the p27-HuD BS and regulate p27 expression. In addition, we performed gain-of-function and loss-of-function experiments. Consistent with the results shown in Figure 4C -H, ectopic expression of HuD increased p27 expression in βTC6 cells, whereas miR-30a-3p decreased it ( Figure 4E ). However, overexpression of miR-30a-3p along with HuD abolished the HuD-mediated upregulation of p27 expression ( Figure 4I ). This finding suggests that HuD and miR-30a-3p might compete for binding to the p27-HuD BS.
Discussion
The majority of patients diagnosed with pancreatic NETs have tumors with significant malignant potential, and the prognosis of patients with progressive advanced pancreatic NETs is poor [1] [2] [3] [4] [5] [6] . However, little is known about the molecular pathogenesis of pancreatic NETs; there is a lack of good prognostic factors with which to stage disease extent, and the current effective treatments for pancreatic NETs are limited. There have been a number of recent advances that have provided insights into the molecular changes and the treatment of advanced pancreatic NETs, suggesting that therapeutic interventions targeting tumor-associated signaling pathways could constitute a future approach for the treatment of pancreatic NETs [1, [38] [39] [40] [41] . Treatment with the multitarget tyrosine kinase inhibitor sunitinib and the oral mammalian target of rapamycin inhibitor everolimus significantly improved PFS as compared with placebo among patients with advanced pancreatic NETs [39, 41] . In addition, targeting β-catenin signaling can suppress the tumorigenesis and growth of pancreatic NETs, and significantly prolongs the survival rate in mice [38] . These findings highlight an imperative need for the identification of new potential molecular targets and the development of therapeutic agents. Thus, a great challenge lies ahead in understanding the molecular mechanisms leading to the development of pancreatic NETs, and further advances in our understanding of the cellular defects and the molecular pathogenesis should contribute to identifying novel prognostic molecular markers that can facilitate the development of appropriate therapeutic strategies.
We provide evidence that pancreatic NETs with loss of HuD expression show an aggressive clinicopathological phenotype. HuD expression is closely associated with tumor size and tumor stage, and can be potentially correlated with pancreatic NET progression. Moreover, in multivariate analysis, HuD loss proved to be an independent predictor of PFS for pancreatic NETs, along with tumor size and angioinvasion. Notably, there is a positive correlation between tumoral HuD loss and significantly reduced PFS. The results of our study also showed the pathological and tumor-suppressive roles of HuD in inhibiting cell proliferation and cell cycle progression. Thus, our results identify HuD as a tumor suppressor in pancreatic NETs, and suggest that it may be a valuable prognostic factor and therapeutic target for pancreatic NETs.
p27 functions as the primary inhibitor of cell cycle progression and proliferation in pancreatic endocrine cells, especially pancreatic β cells [16, 37] , and attenuated expression of p27 in MENs is associated with malignant pancreatic NETs [5, 6, 9] , implying that loss of p27 might be one of the defects present in benign and malignant pancreatic NETs. These data are in line with results obtained with HuD-negative pancreatic NETs, which show significantly decreased p27 expression and increased proliferative capacity, leading to increased tumor size, poor prognosis, and shorter PFS. In agreement with these results, HuD silencing in pancreatic NET cell lines decreased p27 mRNA translation by direct interaction with p27 mRNA, resulting in decreased p27 levels. Therefore, suppressing HuD could facilitate cell cycle progression and the tumorigenesis and growth of pancreatic NETs. Moreover, a positive correlation between HuD and p27 expression was observed in clinical pancreatic NET tissues, further supporting the role of HuD in maintaining p27 abundance and thereby exerting tumor-suppressive effects. In addition, we also found that HuD binds to the 3 ′ -UTR of p27 mRNA and competes with miR-30a-3p for binding to this site. miR-30a-3p decreased p27 expression and inhibited HuD-mediated p27 expression, probably because of competition with HuD for binding to mRNA. These results suggest an interplay between HuD and miR-30a-3p in controlling p27 expression.
In contrast to our findings that HuD enhances p27 mRNA translation and induces cell cycle arrest at the G 1 phase in pancreatic NET cell lines, Kullmann et al proposed that HuD represses p27 mRNA translation, and promotes cell cycle progression in non-neural/neuroendocrine cells, including HeLa and 293 T cells [20] . However, HuD expression is restricted to neural/neuroendocrine cells, and HuD is not present in these non-neural/neuroendocrine cells. In addition, although HuR and HuD are closely related and share several target mRNAs, it is unlikely that they always have the same effects in the same cells or target molecules. For example, HuD, but not HuR, induced neurite outgrowth in PC12 cells [42] . On the basis of our unpublished results, HuD induced p27 expression in human neuroblastoma SH-SY5Y cells, similarly what was found in this study. However, HuR repressed p27 expression in these cells and in other non-neural/neuroendocrine cells, including Hep3B,
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HeLa, HCT116 and MCF7 cells, which is consistent with the previous study [20] . Accordingly, HuR expression was not significantly correlated with pancreatic NET size and progression. In addition, HuD competes with miR-196b for binding to the same site in the 5 ′ -UTR of preproinsulin (Ins2) mRNA to regulate Ins2 mRNA translation [24, 43] , whereas HuR did not associate with Ins2 mRNA [24] . These results suggest that they do not always share the same target mRNAs, and that the difference in effects is due to the interaction with different counterparts.
In addition to neuronal cells, HuD has been found to be expressed in many neuroendocrine cells, including pancreatic islet cells, such as α and β cells [24] . Our study shows that HuD expression is lost in many human pancreatic NETs (26.1%), and these pancreatic NETs show aggressive clinicopathological phenotypes with increased tumor size, poor prognosis and shorter PFS in a p27-dependent manner, suggesting that high expression of HuD might be a suitable biomarker of good prognosis. Although the underlying molecular defects related to HuD loss were not elucidated, these findings pave the way to an understanding of the molecular mechanism leading to pancreatic NETs, and hence the identification of new potential molecular targets.
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